Cargando…

Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia

SIMPLE SUMMARY: Acute Myeloid Leukemia is an aggressive disease with poor outcomes. New targeted therapies that can boost the effects of currently used chemotherapy medications without added toxicity are needed. Targeting an overactive kinase, called the protein Kinase CK2 in AML, helps leukemia cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klink, Morgann, Rahman, Mohammad Atiqur, Song, Chunhua, Dhanyamraju, Pavan Kumar, Ehudin, Melanie, Ding, Yali, Steffens, Sadie, Bhadauria, Preeti, Iyer, Soumya, Aliaga, Cesar, Desai, Dhimant, Huang, Suming, Claxton, David, Sharma, Arati, Gowda, Chandrika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975325/ https://www.ncbi.nlm.nih.gov/pubmed/33807974 http://dx.doi.org/10.3390/cancers13051127

Ejemplares similares

Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2
por: Dovat, Elanora, et al.
Publicado: (2021)

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012)

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
por: Lertsuwan, Jomnarong, et al.
Publicado: (2018)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Transcriptional Regulation of Genes by Ikaros Tumor Suppressor in Acute Lymphoblastic Leukemia
por: Dhanyamraju, Pavan Kumar, et al.
Publicado: (2020)

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study
por: Liu, Hongbo, et al.
Publicado: (2011)

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
por: Girardi, Cristina, et al.
Publicado: (2015)

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
por: D’Amore, Claudio, et al.
Publicado: (2020)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia
por: Payne, Jonathon L, et al.
Publicado: (2020)

CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines
por: Trembley, Janeen H., et al.
Publicado: (2021)

Identification of a Novel Function of CX-4945 as a Splicing Regulator
por: Kim, Hyeongki, et al.
Publicado: (2014)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells
por: Kim, Jiyeon, et al.
Publicado: (2013)

Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity
por: Ding, Yali, et al.
Publicado: (2019)

Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
por: Lee, Joo Youn, et al.
Publicado: (2019)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283
por: Lertsuwan, Jomnarong, et al.
Publicado: (2022)

Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma
por: Liu, Xiangyu, et al.
Publicado: (2019)

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023)

Therapeutic Benefits of Selenium in Hematological Malignancies
por: Ehudin, Melanie A., et al.
Publicado: (2022)

4,5,7‐Trisubstituted indeno[1,2‐b]indole inhibits CK2 activity in tumor cells equivalent to CX‐4945 and shows strong anti‐migratory effects
por: Birus, Robin, et al.
Publicado: (2021)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

PB1810: SELINEXOR COMBINED WITH CX-4945 PROMOTES CELL DEATH BY TARGETING PIK3CD/AKT1/FOXO3 SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Long, Huideng, et al.
Publicado: (2023)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia
por: Annageldiyev, Charyguly, et al.
Publicado: (2020)

Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia
por: Ge, Zheng, et al.
Publicado: (2021)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells
por: Villamañan, Lucía, et al.
Publicado: (2021)

Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2
por: Yadav, Anil Kumar, et al.
Publicado: (2022)

Cellular signaling and epigenetic regulation of gene expression in leukemia
por: Gowda, Chandrika, et al.
Publicado: (2019)

OR02-2 CX-4945 as a Potential Drug for Adrenocortical Carcinoma That Induces Multiple Exon-Skipping and Circular RNA of NR5A1
por: Tanaka, Tomoko, et al.
Publicado: (2019)

The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia
por: Annageldiyev, Charyguly, et al.
Publicado: (2020)

DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia
por: Golla, Upendarrao, et al.
Publicado: (2021)

Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development
por: Dinavahi, Saketh S., et al.
Publicado: (2022)

Macro-CK and CK-BB Contributing to Sham CK-MB Elevation
por: Wada, Yuki, et al.
Publicado: (2017)

Role of aberrant Sonic hedgehog signaling pathway in cancers and developmental anomalies
por: Patel, Trupti N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eiu2mq0nmfis6tl69ps59acrsk